Get Premium to unlock powerful stock data
Horizon Therapeutics PLC logo

Horizon Therapeutics PLC

$ 90.35 +1.01 (+1.13%) 10:08 PM EST
P/E:
24.46
P/B:
4.26
Market Cap:
$ 20.77B
Enterprise V:
$ 21.44B
Volume:
1.66M
Avg Vol (2M):
1.89M
Also Trade In:
Volume:
1.66M
Market Cap $:
20.77B
PE Ratio:
24.46
Avg Vol (2-Month):
1.89M
Enterprise Value $:
21.44B
PB Ratio:
4.26
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Horizon Therapeutics PLC
NAICS : 325412 SIC : 2834
70 St. Stephen’s Green, Dublin 2, IRL, D02 E2X4
Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.65
Equity-to-Asset 0.55
Debt-to-Equity 0.53
Debt-to-EBITDA 2.02
Interest Coverage 10.08
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.25
Distress
Grey
Safe
Beneish M-Score -2.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49.31
9-Day RSI 42.32
14-Day RSI 39.94
6-1 Month Momentum % 7.69
12-1 Month Momentum % 21.7

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.57
Quick Ratio 3.3
Cash Ratio 2.03
Days Inventory 95.28
Days Sales Outstanding 63.36
Days Payable 19.49

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.4

Financials (Next Earnings Date:2022-08-04 Est.)

HZNP's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:HZNP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,769.249
EPS (TTM) ($) 3.65
Beta 1.14
Volatility % 29.86
14-Day RSI 39.94
14-Day ATR ($) 3.862668
20-Day SMA ($) 93.6005
12-1 Month Momentum % 21.7
52-Week Range ($) 82.51 - 120.535
Shares Outstanding (Mil) 229.88

Piotroski F-Score Details

Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Horizon Therapeutics PLC Filings

Document Form Filing Date
No Filing Data

Headlines

See More